14 June 2013 | News | By BioSpectrum Bureau
Singing the MoU - (L-R) Mr Ted Tan, deputy chief executive, SPRING Singapore, Mr Johannes Jansing, Ambassador of the Kingdom of Netherlands to Singapore and Mr Martijn Lamberti, CEO, Maastricht UMC Holding, The Netherlands
Singapore: Spring Singapore and Maastricht University Medical Center of Netherelands have signed a partnership to promote and facilitate cross-border business collaborations between Dutch and Singaporean SMEs and institutions in the areas of healthcare, life sciences and medical technology. This strategic alliance will catalyse co-innovation between enterprises and clinicians, strengthen market access for SMEs, and facilitate business tie-ups between the Netherlands and Singapore.
"Spring Singapore is pleased to partner the Maastricht UMC Holding. This is an important move to promote deeper engagements with our Dutch partners to foster stronger and more strategic cross-border partnerships between Dutch and Singapore research institutions and SMEs, which complement each other and increase our competitive edge to tap growth opportunities in the European and Asian markets," said Mr Ted Tan, deputy CEO, Spring Singapore.
"Maastricht UMC Holding and Spring Singapore will work closely together to achieve new goals and tap collaboration opportunities between Singapore and The Netherlands," said Mr Martijn Lamberti, CEO, Maastricht UMC Holding.
As an enterprise development agency under Singapore's Ministry of Trade and Industry, Spring Singapore supports the growth of promising local SMEs into globally competitive companies. It actively engages overseas partners as codevelopers of new technologies and multipliers for product distribution and link them up with our local SMEs, so as to help them access new markets for growth.
With strong partnership networks in Europe, Maastricht UMC Holding is committed to drive technology innovations through its commercial entities that specialise in various aspects of the medical technology value chain such as research, commercialisation, spin-offs and product development, to further develop current and future commercial research activities.